Company / Operating Cash Flow per Share
Regeneron Pharmaceuticals Operating Cash Flow per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow per Share
$43.79
FY2025
5-year range
$21.20 / $43.79
FY2021-FY2025
Trend
+12.4%
vs FY2024
Sector context
#2 of 212
Health Care
What the data says
Among 212 Health Care companies, Regeneron Pharmaceuticals is in the top 1% for operating cash flow per share. Operating Cash Flow per Share has fluctuated over the past 10 years, ranging from $11.34 in FY2017 to $43.79 in FY2025.
Based on SEC 10-K filings.
43.79 in FY2025 with a 5-year CAGR of +18.0%. Ranks 2nd among 212 companies in Health Care.
Improved from $40.94 to $43.79 over the past 2 years.
Health Care sector context is included.
Operating Cash Flow per Share over time
Growth rates
- 3-Year CAGR
- +24.4%
- 5-Year CAGR
- +18.0%
- 10-Year CAGR
- -
Sector benchmark
+397.4% above sector average
Key checks
Key Insights
- In FY2025, operating cash flow per share increased 12.4% year-over-year.
- Ranks #2 out of 212 companies in the Health Care sector.
- Lowest operating cash flow per share in the period was in FY2017.
Company context
Key Data Points
- Altman Z-Score 3.03 (safe zone, above 2.9 threshold)
- Strong profit margin: 32.1%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash Flow per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $43.79 | +12.4% |
| FY2024 | $38.95 | -4.9% |
| FY2023 | $40.94 | +80.0% |
| FY2022 | $22.75 | +7.3% |
| FY2021 | $21.20 | +10.9% |
| FY2020 | $19.12 | -8.8% |
| FY2019 | $20.97 | +11.1% |
| FY2018 | $18.87 | +66.4% |
| FY2017 | $11.34 | -13.4% |
| FY2016 | $13.10 | +9.6% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026